deltatrials
Terminated PHASE1 INTERVENTIONAL 4-arm NCT05107739

A Study of DeTIL-0255 in Adults With Advanced Malignancies

A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies

Sponsor: Nurix Therapeutics, Inc.

Conditions Cervical Cancer Endometrial Cancer Platinum-resistant Ovarian Cancer
Interventions Drug Product De-TIL-0255
Updated 9 times since 2021 Last updated: May 2, 2024 Started: Dec 22, 2021 Primary completion: May 9, 2023 Completion: May 9, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor Decision

Other Cervical Cancer trials with similar outcome

Browse all Cervical Cancer trials

Listed as NCT05107739, this PHASE1 trial focuses on Cervical Cancer and Endometrial Cancer and remains terminated or withdrawn. Sponsored by Nurix Therapeutics, Inc., it has been updated 9 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshotNot Yet Recruiting~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshotRecruiting~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshotRecruiting~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshotRecruiting~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshotRecruiting~Dec 2022 – ~Jun 2024 · 18 months · monthly snapshotActive Not Recruiting~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Dec 2022 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Oct 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

▶ Show 4 earlier versions

  1. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE1

  2. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  4. Dec 2021 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nurix Therapeutics, Inc.
Data source: Nurix Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations